Related Experiment Video
Updated: Feb 17, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
Inhibition of DNA replication by an anti-PCNA aptamer/PCNA complex
Ewa Kowalska1, Filip Bartnicki1, Ryo Fujisawa2
1Department of Plant Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, Krakow 30-387, Poland.
Abstract:
Proliferating cell nuclear antigen (PCNA) is a multifunctional protein present in the nuclei of eukaryotic cells that plays an important role as a component of the DNA replication machinery, as well as DNA repair systems. PCNA was recently proposed as a potential non-oncogenic target for anti-cancer therapy. In this study, using the Systematic Evolution of Ligands by EXponential enrichment (SELEX) method, we developed a short DNA aptamer that binds human PCNA. In the presence of PCNA, the anti-PCNA aptamer inhibited the activity of human DNA polymerase δ and ϵ at nM concentrations. Moreover, PCNA protected the anti-PCNA aptamer against the exonucleolytic activity of these DNA polymerases. Investigation of the mechanism of anti-PCNA aptamer-dependent inhibition of DNA replication revealed that the aptamer did not block formation, but was a component of PCNA/DNA polymerase δ or ϵ complexes. Additionally, the anti-PCNA aptamer competed with the primer-template DNA for binding to the PCNA/DNA polymerase δ or ϵ complex. Based on the observations, a model of anti-PCNA aptamer/PCNA complex-dependent inhibition of DNA replication was proposed.
Insights
Researchers developed a DNA aptamer targeting proliferating cell nuclear antigen (PCNA), a key protein in DNA replication and repair. This aptamer inhibits DNA polymerase activity, offering potential for novel anti-cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Proliferating cell nuclear antigen (PCNA) is crucial for DNA replication and repair in eukaryotic cells.
- PCNA is recognized as a potential therapeutic target for anti-cancer strategies.
- Understanding PCNA's role is vital for developing targeted cancer treatments.
Purpose of the Study:
- To develop a DNA aptamer that specifically binds to human PCNA.
- To investigate the inhibitory effects of the anti-PCNA aptamer on DNA replication.
- To elucidate the mechanism by which the aptamer inhibits DNA polymerase activity.
Main Methods:
- Systematic Evolution of Ligands by EXponential enrichment (SELEX) was employed to generate the DNA aptamer.
- In vitro assays were conducted to assess the aptamer's binding affinity and inhibitory activity.
- Biochemical experiments were performed to study the interaction between the aptamer, PCNA, and DNA polymerases.
Main Results:
- A novel DNA aptamer targeting human PCNA was successfully developed using SELEX.
- The anti-PCNA aptamer demonstrated potent inhibition of human DNA polymerase δ and ϵ activity at nanomolar concentrations.
- The aptamer was found to protect PCNA from exonucleolytic degradation by DNA polymerases.
- Mechanism studies revealed the aptamer integrates into PCNA/DNA polymerase complexes and competes with DNA for binding.
Conclusions:
- The developed DNA aptamer effectively targets PCNA and inhibits DNA replication.
- The aptamer's mechanism involves interference with PCNA/DNA polymerase complex formation and function.
- This aptamer represents a promising tool for exploring PCNA as a non-oncogenic target in cancer therapy.
More Related Videos
06:43A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
Published on: August 31, 2013
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
Related Concept Videos
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Experimental RNAi